Abstract：
BACKGROUND: Simvastatin (SMV), a lipid lowering drug, can modulate the process of bone regeneration at the molecular and cellular levels. Its effect on the osseointegration of implants has been studied extensively on animals with assuring results with limited research on human subjects.
OBJECTIVE: To estimate the effect of simvastatin gel in the osseointegration of dental implants using bone scintigraphy, Materials and Methods: 20 participants with missing mandibular first molars and D2 type bone were assigned equally to Group A receiving 1.2% simvastatin and Group B receiving Placebo gels during the placement of implants. The participants were subjected to bone scintigraphy to determine the osteoblastic activity at baseline, 30th day and 90th day after implant placement.
RESULTS: Group A revealed a significant increase in osteoblastic activity between baseline, day 30 and 90 (P<.05) with a higher mean of 100.06±21.644% on day 30. Group B revealed a significant increase in osteoblastic activity only between baseline and day 30, and baseline and day 90 (P<.05) whereas there was no difference between day 30 and 90 (P>.05) with a higher mean of 79.20±18.255% on day 30. Bivariate analysis at different time periods revealed a significant difference between groups A and B on day 30.
CONCLUSIONS: Implants placed with 1.2% simvastatin gel showed enhanced osteoblastic activity on the fourth week of implant placement, indicating faster rate of osseointegration at an early stage.
OBJECTIVE: To estimate the effect of simvastatin gel in the osseointegration of dental implants using bone scintigraphy, Materials and Methods: 20 participants with missing mandibular first molars and D2 type bone were assigned equally to Group A receiving 1.2% simvastatin and Group B receiving Placebo gels during the placement of implants. The participants were subjected to bone scintigraphy to determine the osteoblastic activity at baseline, 30th day and 90th day after implant placement.
RESULTS: Group A revealed a significant increase in osteoblastic activity between baseline, day 30 and 90 (P<.05) with a higher mean of 100.06±21.644% on day 30. Group B revealed a significant increase in osteoblastic activity only between baseline and day 30, and baseline and day 90 (P<.05) whereas there was no difference between day 30 and 90 (P>.05) with a higher mean of 79.20±18.255% on day 30. Bivariate analysis at different time periods revealed a significant difference between groups A and B on day 30.
CONCLUSIONS: Implants placed with 1.2% simvastatin gel showed enhanced osteoblastic activity on the fourth week of implant placement, indicating faster rate of osseointegration at an early stage.
摘要：
背景：辛伐他汀（SMV），一种降脂药,可以在分子和细胞水平上调节骨再生的过程。它对植入物骨整合的影响已在动物上进行了广泛的研究，并确保了对人类受试者的有限研究结果。
目的：使用骨闪烁显像评估辛伐他汀凝胶在牙种植体骨整合中的作用，材料和方法：20名缺失下颌第一磨牙和D2型骨的参与者在植入物放置期间被平均分为接受1.2%辛伐他汀的A组和接受安慰剂凝胶的B组。参与者接受骨闪烁显像，以确定基线时的成骨细胞活性，植入后第30天和第90天。
结果：A组显示，第30天和第90天（P<0.05），第30天的平均值为100.06±21.644%。B组显示成骨细胞活性仅在基线和第30天之间以及基线和第90天之间显着增加（P<0.05），而第30天和第90天之间没有差异（P>0.05），第30天的平均值为79.20±18.255％。不同时间段的双变量分析显示，在第30天，A组和B组之间存在显着差异。
结论：植入1.2％辛伐他汀凝胶的植入物在植入的第4周显示出增强的成骨细胞活性，表明早期骨整合速度更快。
目的：使用骨闪烁显像评估辛伐他汀凝胶在牙种植体骨整合中的作用，材料和方法：20名缺失下颌第一磨牙和D2型骨的参与者在植入物放置期间被平均分为接受1.2%辛伐他汀的A组和接受安慰剂凝胶的B组。参与者接受骨闪烁显像，以确定基线时的成骨细胞活性，植入后第30天和第90天。
结果：A组显示，第30天和第90天（P<0.05），第30天的平均值为100.06±21.644%。B组显示成骨细胞活性仅在基线和第30天之间以及基线和第90天之间显着增加（P<0.05），而第30天和第90天之间没有差异（P>0.05），第30天的平均值为79.20±18.255％。不同时间段的双变量分析显示，在第30天，A组和B组之间存在显着差异。
结论：植入1.2％辛伐他汀凝胶的植入物在植入的第4周显示出增强的成骨细胞活性，表明早期骨整合速度更快。
